Health care stocks were leaning lower premarket Tuesday, with the iShares Biotechnology ETF (IBB) declining 0.5% and The Health Care Select Sector SPDR Fund (XLV) down 0.7%.

Rocket Pharmaceuticals (RCKT) shares were 3% higher, reversing a more than 2% decline from the previous day when the company said it will not begin patient enrollment for the phase 2 trial of its experimental RP-L301 gene therapy until next year as it is currently directing resources toward other programs.

Spyre Therapeutics (SYRE) shares were down more than 3% after the company priced an underwritten public offering of about 7.3 million shares of its common stock at $27.50 apiece for expected gross proceeds of $200 million.

Medtronic (MDT) shares were 1% lower even after the company reported higher fiscal Q2 non-GAAP earnings and net sales.